Viright - Jupiter Biomedical Research
Alternative Names: VirightLatest Information Update: 28 Jul 2023
At a glance
- Originator Jupiter Biomedical Research
- Developer Jupiter Biomedical Research; Ligand Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Glioblastoma
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glioblastoma in Canada (Intraperitoneal, Injection)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glioblastoma in Canada (IV, Injection)
- 06 Jun 2022 Phase-I clinical trials in Solid tumours in Canada (Intraperitoneal), before June 2022 (Ligand Pharmaceuticals pipeline, June 2022)